lazertinib,amivantamab,daratumumab,ciltacabtagene autoleucel,teclistamab,talquetamab,erdafitinib
janssen,genmab,yuhan corp
['lazertinib', 'carvykti', 'teclistamab', 'lung', 'bladder', 'daratumumab', 'balversa', 'talquetamab', 'amivantamab', '$jnj']
j&amp;j $jnj #asco23 key data myeloma: carvykti car-t bcma myeloma: alquetamab (cd138) + daratumumab (cd38) myeloma: talquetamab (cd138) + teclistamab (bifx cd19/btk) bladder: balversa (fgfr) lung egfr: amivantamab (egfr) &amp; lazertinib (alk) (link to subst***ack in bio) 
Bi-Weekly Biotech Updates: Public & Private Market Updates, Company Building, Financing, Exit Strategies, and Emerging Science Trends | Current: Biotech VC